Allarity Therapeutics, Inc. (ALLR) Stock Analysis & Investment Frameworks

Allarity Therapeutics, Inc. (ALLR) stock analysis on Invetso. Review Allarity Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Allarity Therapeutics, Inc. Company Overview

Allarity Therapeutics, Inc. Key Financial Metrics

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Allarity Therapeutics, Inc. Investment Frameworks

Invetso analyzes Allarity Therapeutics, Inc. (ALLR) across the following frameworks:

Explore More ALLR Research